Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Vopr Onkol ; 59(1): 123-5, 2013.
Artigo em Russo | MEDLINE | ID: mdl-23814839
4.
Adv Gerontol ; 18: 76-85, 2006.
Artigo em Russo | MEDLINE | ID: mdl-16676802

RESUMO

The aim of our study was to evaluate the efficacy and safety of 3-drugs regimen: T 75 mg/m2 d2 + P 75 mg/m2 d2 + F 500 mg/m2 x 3h d 1-3 every 28 days. 31 patients (pts) with morphologically proven advanced gastric cancer of the age 29-77 years (median 61.0) have been treated with this regimen. They received 138 cycles (1-10, median 4.0 cycles per pt). The response rate was evaluated in pts received > or =2 cycles: CR 1/27 (3.7%), PR 12/27 (44.4%), SD 7/27 (25.9%), PD 7/27 (25.9%). The median duration of CR+PR--4.5 mon (1.1-9.9), of SD--6.8 mon (3.0-10.7). Median TTP--5.5 mon. Overall survival: median--11.5 mon, 1-year--46.6%. PS improvement was observed in 54.8%pts, symptomatic improvement--in 71% pts. Toxicity per pt (per cycle) was moderate. There were 11 elderly among these pts. We didn't receive any significant differences in efficacy and severe toxicity in this group compared to non-elderly pts. We observed 55.6% PR, 33.3% SD, 11.1% PD, TTP--4.6 mon, median OS-7.5 mon. in elderly and 5.6% CR, 38.9% PR, 22.2% SD, 33.3 % PD, TTP--6.1 mon, median OS-12.3 mon for non-elderly pts. But dose reduction was performed more frequently in the elderly then non-elderly: 63.6% vs 30.0% pts (p = 0.07) in 64.8% vs 19.1% cycles (p < 0.0001). We consider this regimen to be effective and well tolerated both for elderly and for non-elderly patients.


Assuntos
Adenocarcinoma/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica , Neoplasias Gástricas/tratamento farmacológico , Adenocarcinoma/patologia , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Cisplatino/administração & dosagem , Cisplatino/efeitos adversos , Cisplatino/uso terapêutico , Intervalo Livre de Doença , Docetaxel , Esquema de Medicação , Feminino , Fluoruracila/administração & dosagem , Fluoruracila/efeitos adversos , Fluoruracila/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica , Neoplasias Gástricas/patologia , Taxoides/administração & dosagem , Taxoides/efeitos adversos , Taxoides/uso terapêutico , Resultado do Tratamento
5.
Vopr Onkol ; 50(4): 492-500, 2004.
Artigo em Russo | MEDLINE | ID: mdl-15605777

Assuntos
Antineoplásicos Fitogênicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Taxoides/uso terapêutico , Antraciclinas/administração & dosagem , Antraciclinas/uso terapêutico , Antibióticos Antineoplásicos/administração & dosagem , Antibióticos Antineoplásicos/uso terapêutico , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados , Antineoplásicos Alquilantes/administração & dosagem , Antineoplásicos Alquilantes/uso terapêutico , Antineoplásicos Fitogênicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/mortalidade , Neoplasias da Mama/secundário , Neoplasias da Mama/cirurgia , Carboplatina/administração & dosagem , Carboplatina/uso terapêutico , Quimioterapia Adjuvante , Ensaios Clínicos Fase III como Assunto , Ciclofosfamida/administração & dosagem , Ciclofosfamida/uso terapêutico , Interpretação Estatística de Dados , Progressão da Doença , Docetaxel , Doxorrubicina/administração & dosagem , Doxorrubicina/uso terapêutico , Epirubicina/administração & dosagem , Epirubicina/uso terapêutico , Feminino , Humanos , Terapia Neoadjuvante , Metástase Neoplásica , Paclitaxel/administração & dosagem , Paclitaxel/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Medição de Risco , Fatores de Risco , Taxoides/administração & dosagem , Fatores de Tempo , Trastuzumab
6.
Adv Gerontol ; 11: 121-9, 2003.
Artigo em Russo | MEDLINE | ID: mdl-12820532

RESUMO

Colorectal and gastric cancer in usually diagnosed in elderly patients. In metastatic disease systemic chemotherapy has been shown to be of clinical benefit for patients in term of prolongation of survival, symptomatic improvement and quality of life. Compared to its younger counterparts 5-FU-based treatment appears to be equally effective and more toxic according to some reports. Data regarding raltitrexed, oral fluoropyprimidines, Campto or oxaliplatin are limited but suggest no age-specific differences in activity or toxicity. Our experience of using chemotherapy with 5-FU-based combinations, oxaliplatin, Campto, raltitrexed in limited groups of elderly patients confirms this opinion.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias do Colo/tratamento farmacológico , Neoplasias Gástricas/tratamento farmacológico , Idoso , Neoplasias do Colo/patologia , Humanos , Neoplasias Gástricas/patologia
8.
Adv Gerontol ; 10: 126-30, 2002.
Artigo em Russo | MEDLINE | ID: mdl-12577700

RESUMO

Elderly patients as a rule have modifications related to age (physiologic changes) and to other concomitant diseases (comorbidity). The glomerular filtration rate decreases with age. Before any chemotherapy is started creatinine clearance should be performed, and the doses of cytotoxic agents with active renal excretion should be modified according to creatinine clearance. Decreased liver blood flow may influence drug disposition. Some changes in liver function do occur with advanced age and may form the basis of some drug toxicities. The lean body mass in elderly people is characterized by an increase in fat, with a decrease in intracellular water, and this change, along with a decrease in serum albumin, can considerably modify drug pharmacokinetics. Decreasing in bone marrow reserve related to age increases the risk of myelotoxicity after cytotoxic therapy. Nevertheless chemotherapy may be tolerable and successful in elderly patients carefully selected. This article contains information about elderly cancer patients treated with cisplatin-based combinations (cisplatin + Vepesid + Nitrullyn, cisplatin + taxotere). There were no serious side effects.


Assuntos
Antineoplásicos/uso terapêutico , Neoplasias/tratamento farmacológico , Idoso , Antineoplásicos/efeitos adversos , Antineoplásicos/farmacocinética , Creatinina/urina , Humanos , Testes de Função Hepática , Neoplasias/fisiopatologia
10.
Vopr Onkol ; 47(6): 680-3, 2001.
Artigo em Russo | MEDLINE | ID: mdl-11826488

RESUMO

Hematologic thrombopenia and leukopenia formation limits use of nitrullin as a toxic hazard. The drug showed moderate effect in treating inoperable non-small cell cancer of the lung and satisfactory end results. The treatment had marked symptomatic effect in patients with this cancer and, as a consequence, improved the quality of life. Nutrullin had immuno-modulating effect. Its application alone or in combination with VPN showed good results in the management of small-cell cancer of the lung.


Assuntos
Adenocarcinoma/tratamento farmacológico , Antineoplásicos/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Carcinoma de Células Pequenas/tratamento farmacológico , Carcinoma de Células Escamosas/tratamento farmacológico , Citrulina/análogos & derivados , Citrulina/uso terapêutico , Neoplasias Pulmonares/tratamento farmacológico , Compostos de Nitrosoureia/uso terapêutico , Adenocarcinoma/mortalidade , Adulto , Idoso , Antineoplásicos/efeitos adversos , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Carcinoma de Células Pequenas/mortalidade , Carcinoma de Células Escamosas/mortalidade , Citrulina/efeitos adversos , Humanos , Neoplasias Pulmonares/mortalidade , Metástase Linfática , Pessoa de Meia-Idade , Metástase Neoplásica , Compostos de Nitrosoureia/efeitos adversos , Fatores de Tempo
12.
Antibiotiki ; 29(6): 463-8, 1984 Jun.
Artigo em Russo | MEDLINE | ID: mdl-6476811

RESUMO

A total of 119 patients were treated for disseminated cancer of the mammary gland according to two schemes with the use of adriablastin. It was shown that in the treatment of metastases into the bones adriablastin was the drug of choice. The treatment of such patients with it may be effective. The analgetic action of the drug was noted in 80 per cent of the patients. The roentgenologically observed objective effect of the drug was provided by the doses higher than 300 mg and the treatment period of not less than 4 months. In the treatment of patients with metastases of other localization the schemes with the use of adriablastin had no advantage over the Cooper scheme.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias Ósseas/tratamento farmacológico , Neoplasias Ósseas/secundário , Ciclofosfamida/administração & dosagem , Doxorrubicina/administração & dosagem , Avaliação de Medicamentos , Feminino , Fluoruracila/administração & dosagem , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/secundário , Metástase Linfática , Metotrexato/administração & dosagem , Neoplasias Cutâneas/tratamento farmacológico , Neoplasias Cutâneas/secundário , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...